Xenetic Biosciences, Inc. (XBIO) fundamentals score
in the U.S. after lung cancer. CRC is the third most commonly diagnosed cancer in males and the second in females, globally, according
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 5.2 out of 10, Mixed fundamentals
- Growth: 4.5/10
- Profitability: 3.3/10
- Financial health: 5.8/10
- Earnings quality: 7.2/10
- Valuation: 6.7/10
Scores are calculated from Xenetic Biosciences, Inc.’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10